Edition:
United States

Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

1.90USD
17 May 2019
Change (% chg)

$-0.03 (-1.55%)
Prev Close
$1.93
Open
$1.93
Day's High
$1.93
Day's Low
$1.79
Volume
77,137
Avg. Vol
137,764
52-wk High
$10.30
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Aytu Bioscience Inc Reports 291% Revenue Growth In Q3 FY19
Tuesday, 14 May 2019 08:20am EDT 

May 14 (Reuters) - Aytu BioScience Inc ::AYTU BIOSCIENCE REPORTS 291% REVENUE GROWTH IN Q3 FY19.Q3 REVENUE $2.4 MILLION.CASH BALANCE OF APPROXIMATELY $15 MILLION ON MARCH 31, 2019.QTRLY LOSS PER SHARE $0.50.  Full Article

Aytu Bioscience - On Nov 2, 2018, Co Entered Into A License, Development, Manufacturing And Supply Agreement With Tris Pharma - SEC Filing
Monday, 5 Nov 2018 08:21am EST 

Aytu BioScience Inc ::AYTU BIOSCIENCE - ON NOV 2, 2018, CO ENTERED INTO A LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT WITH TRIS PHARMA - SEC FILING.AYTU BIOSCIENCE - AS PER AGREEMENT, TRIS GRANTED TO CO AN EXCLUSIVE LICENSE IN UNITED STATES RELATED TO TUZISTRA XR.AYTU BIOSCIENCE INC - ALONG WITH TUZISTRA XR, CO HAS LICENSED A COMPLEMENTARY ANTITUSSIVE PRODUCT PENDING FDA APPROVAL.AYTU BIOSCIENCE INC - AS PART OF TRANSACTION, CO ALSO PLANS TO ENTER INTO A STRATEGIC FINANCING WITH ARMISTICE CAPITAL, LLC.AYTU BIOSCIENCE - UNDER TERMS OF FINANCING, ARMISTICE EXPECTED TO PROVIDE CO WITH UP TO $5 MILLION IN FORM OF 3 YEAR NOTE, SECURED BY TUZISTRA REVENUE STREAMS.AYTU BIOSCIENCE - CO WILL PAY TRIS PHARMA MILESTONE PAYMENTS AND CERTAIN ROYALTY FEES THROUGH TERM FOR TUZISTRA XR AND CCP-08.  Full Article

CVI Investments Reports Passive Stake Of 9.9 Pct In Aytu Bioscience As Of Oct. 5, 2018
Friday, 12 Oct 2018 09:19am EDT 

Oct 12 (Reuters) - Aytu BioScience Inc ::CVI INVESTMENTS, INC REPORTS PASSIVE STAKE OF 9.9 PERCENT IN AYTU BIOSCIENCE AS OF OCTOBER 5, 2018 - SEC FILING.  Full Article

Aytu Bioscience Q3 Loss Per Share $0.24
Monday, 14 May 2018 04:05pm EDT 

May 14 (Reuters) - Aytu BioScience Inc ::AYTU BIOSCIENCE PROVIDES FISCAL THIRD QUARTER 2018 BUSINESS UPDATE.AYTU BIOSCIENCE INC - QTRLY LOSS PER SHARE $0.24.  Full Article

Aytu Bioscience Q2 Revenue $1.1 Mln, An Increase Of 32 pct
Thursday, 8 Feb 2018 04:01pm EST 

Feb 8 (Reuters) - Aytu Bioscience Inc ::AYTU BIOSCIENCE INC - TOTAL REVENUE FOR Q2 WAS ABOUT $1.1 MILLION, AN INCREASE OF 32%.AYTU BIOSCIENCE INC QTRLY LOSS PER SHARE $0.89.  Full Article

Acerus Pharmaceuticals Announces C$1.6 Million Worth Purchase Orders
Thursday, 30 Nov 2017 07:00am EST 

Nov 30 (Reuters) - Acerus Pharmaceuticals Corporation ::ACERUS PHARMACEUTICALS - ANNOUNCED C$1.6 MILLION WORTH OF NATESTO PURCHASE ORDERS FROM ITS U.S. LICENSEE AYTU BIOSCIENCE.  Full Article

Aytu Bioscience files for mixed shelf of upto $100 mln
Wednesday, 22 Nov 2017 05:30pm EST 

Nov 22 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing.  Full Article

Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system
Tuesday, 7 Nov 2017 08:05am EST 

Nov 7 (Reuters) - Aytu Bioscience Inc ::Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system for male infertility.Aytu Bioscience Inc - ‍expects to announce a distribution partner and launch Mioxsys for clinical use in coming quarters​.Aytu Bioscience Inc - ‍has engaged in australian market development activities and is in early discussions with distribution partners​.Aytu Bioscience - ‍Mioxsys been approved by TGA as an aid in diagnostic assessment of semen quality for patients undergoing male infertility evaluation​.  Full Article

Aytu Bioscience CFO Gregory Gould resigns
Friday, 27 Oct 2017 04:51pm EDT 

Oct 27 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc - ‍on October 26, 2017, Gregory A. Gould resigned as Chief Financial Officer​.Aytu Bioscience Inc - ‍Gould's resignation will become effective on November 15, 2017 -​ SEC filing.  Full Article